LogicBio Therapeutics

96 articles with LogicBio Therapeutics

• Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® Therapeutics

  11/16/2022

  Alexion, AstraZeneca Rare Disease, today announced the completion of its acquisition of LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a pioneering genomic medicine company.

• LogicBio Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

  11/14/2022

  LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a clinical-stage genetic medicine company, today reported financial results for the third quarter ended September 30, 2022 and provided business updates.

• Alexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic Medicine

  10/3/2022

  LogicBio® Therapeutics, Inc., a pioneering clinical-stage genomic medicine company, announced that it has entered into a definitive agreement under which AstraZeneca Rare Disease will acquire LogicBio.

• 

  AstraZeneca Acquires LogicBio for $68 Million to Bolster Genomics Pipeline

  10/3/2022

  AstraZeneca is acquiring LogicBio Therapeutics in a deal worth $68 million. The deal bolsters AstraZeneca’s efforts to braoden its portfolio in genomics and rare diseases.

• LogicBio® Therapeutics Announces Pre-Clinical Results for mLB-001 Published in Peer-reviewed Journal PLOS ONE

  9/21/2022

  LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that results from the company's preclinical research study entitled "Novel AAV-mediated genome editing therapy prevents metabolic decompensation in a mouse model of methylmalonic acidemia" have been published in the peer-reviewed journal PLOS ONE.

• LogicBio Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

  8/15/2022

  LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a clinical-stage genetic medicine company, today reported financial results for the second quarter ended June 30, 2022, and provided business updates, including early clinical data from its ongoing SUNRISE trial evaluating LB-001 in pediatric patients with severe methylmalonic acidemia (MMA).

• Exothera announces industrial scale AAV manufacturing collaboration with LogicBio Therapeutics and Polyplus

  6/15/2022

  Exothera SA announced a collaboration with LogicBio® Therapeutics and Polyplus-transfection® SA. for the development of a highly scalable AAV manufacturing platform with a capacity from 200 L to 2,000 L.

• LogicBio® Therapeutics to Present at H.C. Wainwright Global Investment Conference

  5/17/2022

  LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Frederic Chereau, will present a company overview at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022.

• LogicBio Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Business Updates

  5/16/2022

  LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a clinical-stage company advancing a diversified pipeline of genetic medicines addressing rare disorders from infancy through adulthood, today reported financial results for the quarter ended March 31, 2022, and highlighted recent business updates.

• 

  Clinical Catch-Up: Updates for Achilles, Logic Bio, Roche and More

  5/16/2022

  Achilles dosed the first patient in a Phase I/IIa advanced NSCLC trial, Logic Bio's pediatric methylmalonic acidemia study is back up and running and another look at Roche's TIGIT flop.

• LogicBio Therapeutics Announces Upcoming Presentations on GeneRide Development Candidate and Multiple Advancements in AAV Manufacturing Processes at ASGCT Annual Meeting

  5/11/2022

  LogicBio® Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that it will present four abstracts highlighting the company's GeneRide technology in preclinical hereditary tyrosinemia type 1 (HT1) models and optimized adeno-associated virus (AAV) manufacturing processes during the American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting, held May 16-19, 2022, in Washington D.C. and virtually.

• 

  LogicBio Cleared to Continue Dosing in Pediatric MMA Trial

  5/9/2022

  LogicBio Therapeutics has received the green light to continue dosing participants in its Phase I/II Sunrise trial, following a clinical hold placed by the FDA due to adverse events in pediatric patients.

• LogicBio Therapeutics Announces FDA Lifts Clinical Hold on SUNRISE Trial in Pediatric Patients with Methylmalonic Acidemia

  5/9/2022

  LogicBio® Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the company's LB-001 Investigational New Drug Application (IND), allowing patient enrollment to resume in the Phase 1/2 SUNRISE trial for pediatric patients with methylmalonic acidemia.

• 

  Rapid Whole Genome Sequencing in Infants Could Even Playing Field for Treatment

  4/11/2022

  What if infants with genetic illnesses could be diagnosed in a matter of days? New research surrounding rapid whole genome sequencing suggests that soon, they could be.

• LogicBio Therapeutics to Present at H.C. Wainwright Gene Therapy and Gene Editing Conference

  3/23/2022

  LogicBio® Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Frederic Chereau, will present a company overview at the H.C. Wainwright Gene Therapy and Gene Editing Conference.

• LogicBio Therapeutics to Present at Barclays Global Healthcare Conference

  3/8/2022

  LogicBio® Therapeutics, Inc., a clinical-stage genetic medicine company, announced that president and chief executive officer, Frederic Chereau, will participate in a fireside chat during the Barclays Global Healthcare Conference on March 15, 2022, at 3:20 p.m. ET.

• LogicBio Therapeutics Reports Full Year 2021 Financial Results and Provides Business Updates

  3/4/2022

  LogicBio® Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today reported financial results for the year ended December 31, 2021, and provided business updates.

• 

  Clinical Catch-Up: January 31-February 4

  2/7/2022

  It was a relatively quiet week for clinical trial announcements. Here’s a look.
• 

  Intellia Broadens CRISPR Capabilities with Pick Up of Rewrite Therapeutics

  2/3/2022

  On Thursday, Intellia announced it had paid Rewrite shareholders $45 million upfront. Additionally, the transaction involved a transfer of $155 million in the form of Intellia common stock and cash.

• LogicBio Therapeutics Provides Update on LB-001 Clinical Development Program

  2/2/2022

  LogicBio Therapeutics, Inc., a clinical-stage genetic medicine company, provided an update on the LB-001 clinical development program.